Da Zen Theranostics, Inc. was founded by two professors, Dr. Leland W.K. Chung and Dr. Haiyen E. Zhau, who have devoted their academic careers (over 50 years each) to cancer research. The company was formed with the intention of bringing effective cancer treatment to late stage cancer patients. The husband-and-wife team named their company Da Zen 大 仁 which means ‘great kindness’ in Chinese. Dr. Chung is Chairman of the Board for Da Zen.
The research and development of products and technologies at Da Zen has been led by Drs. Chung and Zhau, in collaboration with their colleagues at M.D. Anderson Cancer Center (Houston, TX), Emory University (Atlanta, GA), and Cedars-Sinai Medical Center (Los Angeles, CA)
Da Zen Theranostics, Inc. (U.S.) was initially incorporated in the State of Delaware in 2012 as an LLP, but later converted to a C-Corp and registered in the State of California in 2017. Da Zen (U.S.) has a wholly owned subsidiary in China under the name Da Zen Pharmaceutical.
The subsidiary shares patent licensing rights and ownership with the U.S. parent company. Da Zen Pharmaceutical (China) started its operations in Chengdu in January of 2019. The total investment by the parent company will eventually reach 50M RMB.
Da Zen has filed ten exclusively licensed or proprietary patent protections, two which have been granted. In addition, the company has obtained support from University of Texas Southwestern Medical Center to commence research with the drug conjugate DZ-004 and is applying for funding to support development of this cancer therapeutic drug as a deliverable. Currently, two of Da Zen’s drug conjugates, DZ-002 and DZ-003, are in the research and development pipeline.